How we manage invasive fungal disease in acute myeloid leukemia patients with Glucose 6 Dehydrogenase deficiency
Main Article Content
Keywords
G6PD, Aspergillosis, Candida, Acute Myeloid Leukemia, Fungal Infection
Downloads
Download data is not yet available.
Abstract 1433
PDF Downloads 679
HTML Downloads 844
Referring article Downloads 0
References
[1]Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin North Am. 2016; 30:373–93.
[2]Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014; 164:469–480.
[3] Spolarics Z, Siddiqi M, Siegel JH, et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med. 2001; 29:728-36.
[4]Abu-Osba YK, Mallouh AA, Hann RW. Incidence and causes of sepsis in glucose-6-phosphate dehydrogenase-deficient newborn infants. J Pediatr. 1989; 114:748-52.
[5]Meloni T, Forteleoni G, Ena F, et al. Glucose-6-phosphate dehydrogenase deficiency and bacterial infections in northern Sardinia. J Pediatr. 1991; 118:909-11.
[6]Rodey GH, Jacob HS, Holmes B, et al. Leucocyte G6PD levels and bacterial activity. Lancet, 1970; 1:355-6.
[7] Sanna M, Caocci G, Ledda A, et al. Glucose-6-Phosphate Deidhrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. Leuk Lymphoma. 2017; Epub ahead of print
[8]Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Seidlein L.Malar J. 2013;12:391
[9]Lamoth F, Cruciani M, Mengoli C, et al. Third European Conference on Infections in Leukemia (ECIL-3). ?-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633-43
[10]Pappas GP. Clinical Infectious Diseases Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious DiseasesSociety of America.Clin Infect Dis. 2016;62:e1-50.
[11]Tissot F, Agrawal S, Pagano L. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017; 102:433-444.
[2]Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014; 164:469–480.
[3] Spolarics Z, Siddiqi M, Siegel JH, et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med. 2001; 29:728-36.
[4]Abu-Osba YK, Mallouh AA, Hann RW. Incidence and causes of sepsis in glucose-6-phosphate dehydrogenase-deficient newborn infants. J Pediatr. 1989; 114:748-52.
[5]Meloni T, Forteleoni G, Ena F, et al. Glucose-6-phosphate dehydrogenase deficiency and bacterial infections in northern Sardinia. J Pediatr. 1991; 118:909-11.
[6]Rodey GH, Jacob HS, Holmes B, et al. Leucocyte G6PD levels and bacterial activity. Lancet, 1970; 1:355-6.
[7] Sanna M, Caocci G, Ledda A, et al. Glucose-6-Phosphate Deidhrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. Leuk Lymphoma. 2017; Epub ahead of print
[8]Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Seidlein L.Malar J. 2013;12:391
[9]Lamoth F, Cruciani M, Mengoli C, et al. Third European Conference on Infections in Leukemia (ECIL-3). ?-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633-43
[10]Pappas GP. Clinical Infectious Diseases Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious DiseasesSociety of America.Clin Infect Dis. 2016;62:e1-50.
[11]Tissot F, Agrawal S, Pagano L. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017; 102:433-444.